(NASDAQ: OABI) Omniab's forecast annual revenue growth rate of 35.15% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.37%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.75%.
Omniab's revenue in 2024 is $34,164,000.On average, 5 Wall Street analysts forecast OABI's revenue for 2024 to be $3,839,157,536, with the lowest OABI revenue forecast at $3,396,655,334, and the highest OABI revenue forecast at $4,556,203,189. On average, 5 Wall Street analysts forecast OABI's revenue for 2025 to be $6,884,668,984, with the lowest OABI revenue forecast at $5,504,924,162, and the highest OABI revenue forecast at $8,667,327,404.
In 2026, OABI is forecast to generate $9,861,193,191 in revenue, with the lowest revenue forecast at $7,660,043,408 and the highest revenue forecast at $11,712,604,600.